Journal of Neurology

, Volume 254, Supplement 5, pp 19–26

Initiation of symptomatic therapy in Parkinson's disease: dopamine agonists versus levodopa



Parkinson's disease (PD) is a chronic progressive neurodegenerative disease and its early treatment is of prime importance. Early treatment of PD has several goals: to increase the patient's quality of life and to have symptomatic benefits, to slow disease progression, and to prevent treatment-related morbidity in the long-term. The treatment strategy in patients with de novo, early-stage PD has numerous facets and should be individually tailored. Levodopa is the gold standard for the symptomatic treatment of PD. However, despite clinical experience with levodopa for more than three decades, there are still unanswered questions about its effect on disease progression and delayed motor complications. There is now an increasing use of dopamine agonists as effective early monotherapy in the treatment of PD. Evidence from randomized-controlled trials has shown that initiating symptomatic therapy with dopamine agonists reduces the risk of development of motor complications and there are also some data suggesting that such treatment may slow disease progression. This article reviews the laboratory and clinical evidence on the therapeutic options in early de novo PD so as to help physicians establish the best-fitting treatment strategy adapted for the individual patient.

Key words

Parkinson's disease treatment dopamine agonists levodopa 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, Taylor RL, Sanchez-Ramos J, O'Brien CF (1997) Ropinirole for the treatment of early Parkinson's disease. Neurology 49:393–399PubMedGoogle Scholar
  2. 2.
    Barone P, Bravi D, Bernejo-Pareja F, Marconi R, Kulisevsky J, Malagù S, Weiser R, Rost N (1999) Pergolide monotherapy in the treatment of early PD: a randomized controlled study. Neurology 53:573–579PubMedGoogle Scholar
  3. 3.
    Bedard PJ, Di Paolo, Falardeau P, Boucher R (1986) Chronic treatment with levodopa, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding. Brain Res 379:294–299PubMedCrossRefGoogle Scholar
  4. 4.
    Beyer PL, Palarino MY, Michalek D, Busenbark K, Koller WC (1995) Weight change and body composition in patients with Parkinson's disease. J Am Diet Assoc 95:979–983PubMedCrossRefGoogle Scholar
  5. 5.
    Blanchet PJ, Calon F, Martel JC, Bedard PJ, Di Paolo T, Walters RR, Piercey MF (1995) Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther 272:854–859PubMedGoogle Scholar
  6. 6.
    Block G, Liss C, Scott R, Irr J, Nibbelink D (1997) Comparison of immediaterelease and controlled release carbidopa/ levodopa in Parkinson's disease.A multicenter 5-year study. Eur Neurol 37:23–27PubMedGoogle Scholar
  7. 7.
    Cassarino DS, Fall CP, Smith TS, Bennet JP Jr (1998) Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J Neurochem 71:295–301PubMedCrossRefGoogle Scholar
  8. 8.
    Clarke CE, Sambrook MA, Mitchell IJ, Crossman AR (1987) Levodopa induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP). J Neurol Sci 78:273–280PubMedCrossRefGoogle Scholar
  9. 9.
    Corrigan MH, Denahan AQ, Eugene Wright C, Ragual RJ, Evans DL (2000) Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 11:58–65PubMedCrossRefGoogle Scholar
  10. 10.
    Datla KP, Blunt SB, Dexter D (2001) Chronic L-dopa administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-hydroxydopamine or FeCl3 nigrostriatal lesions. Mov Disord 16:424–434PubMedCrossRefGoogle Scholar
  11. 11.
    Djaldetti R, Inzelberg R, Giladi N, Korczyn AD, Peretz-Aharon Y, Rabey MJ, Herishano Y, Honigman S, Badarny S, Melamed E (2002) Oral solution of levodopa ethyl ester for treatment of response fluctuations in patients with advanced Parkinson's disease. Mov Disord 17:297–302PubMedCrossRefGoogle Scholar
  12. 12.
    Dupont E, Anderson A, Boqs J, Boisen E, Borgmann R, Helgetveit AC, Kjaer AC, Kristensen TN, Mikkelsen B, Pakkenberg H, Presthus J, Stien R, Worm-Petersen J, Buch D (1996) Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand 93:14–20PubMedCrossRefGoogle Scholar
  13. 13.
    Etminan M, Samii A, Takkouche B, Rochon P (2001) Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease. A meta-analysis of randomised controlled trials. Drug Safety 24:863–868PubMedCrossRefGoogle Scholar
  14. 14.
    Freeman AS, Meltzer LT, Bunney BS (1985) Firing properties of substantia nigra dopaminergic neurons in freely moving rats. Life Sci 36:1983–1994PubMedCrossRefGoogle Scholar
  15. 15.
    Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ Jr, Sibley DR (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250:1429–1432PubMedCrossRefGoogle Scholar
  16. 16.
    Goetz CG, Poewe W, Rascol O, Sampaio C (2005) Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001–2004. Mov Disord 20:523–539PubMedCrossRefGoogle Scholar
  17. 17.
    Grondin R, Goulet M, Di Paolo T, Bedard PJ (1996) Cabergoline, a long acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drugnaïve primates. Brain Res 735:298–306PubMedCrossRefGoogle Scholar
  18. 18.
    Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J (2002) Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 287:455–463PubMedCrossRefGoogle Scholar
  19. 19.
    Högl B, Seppi K, Brandauer E, Glatzl S, Frauscher B, Niedermüller U, Wenning G, Poewe W (2003) Increased daytime sleepiness in Parkinson's disease: a questionnaire survey. Mov Disord 18:319–323PubMedCrossRefGoogle Scholar
  20. 20.
    Jenner P (2002) Pharmacology of dopamine agonists in the treatment of Parkinson's disease. Neurology 58 (Suppl 1):S1–S8PubMedGoogle Scholar
  21. 21.
    Johnson SW, Seutin V, North RA (1992) Burst firing in dopamine neurons induced by N-methyl-D-aspartate: role of electrogenic sodium pump. Science 258:665–667PubMedCrossRefGoogle Scholar
  22. 22.
    King DF, Cooper JM, Schapira AHV (2001) Pramipexole protects against MPP + toxicity in SHSY5Y cells by maintaining mitochondrial membrane potential. Neurology 56:A377–A388Google Scholar
  23. 23.
    Kitamura Y, Shimohama S, Kamoshima W, Ota T, Matsuoka Y, Nomura Y, Smith MA, Perry G, Whitehouse PJ, Taniguchi T (1998) Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-I and CPP32, in Alzheimer’s disease. Brain Res 780:260–269PubMedCrossRefGoogle Scholar
  24. 24.
    Koller WC (2002) Treatment of early Parkinson's disease. Neurology 58 (Suppl 1):S79–S86PubMedGoogle Scholar
  25. 25.
    Lees AJ, Katzenschlager R, Head J, Ben- Shlomo Y, on behalf of the Parkinson's Disease Research Group on the United Kingdom (2001) Ten-year follow-up of three different initial treatments in denovo PDA randomized trial. Neurology 57:1687–1694PubMedGoogle Scholar
  26. 26.
    Melamed E, Offen D, Shirvan A, Djaldetti R, Barzilai A, Ziv I (1998) Levodopa toxicity and apoptosis. Ann Neurol 44:S149–S154PubMedGoogle Scholar
  27. 27.
    Montastruc JL, Desboeuf K, Lapeyre-Mestre M, Senard JM, Rascol O, Brefel-Courbon C (2001) Long-term mortality results on the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease. Mov Disord 16:511–514PubMedCrossRefGoogle Scholar
  28. 28.
    Montastruc JL, Rascol O, Senard JM, Rascol A (1994) A randomized controlled study comparing bromocriptine to which levodopa was later added, versus levodopa alone in patients with Parkinson's disease: A five year follow-up. J Neurol Neurosurg Psychiatry 57:1034–1038PubMedGoogle Scholar
  29. 29.
    Murer MG, Dziewczapolski G, Menalled LB, García MC, Agid Y, Gershanik O, Raisman-Vozari R (1998) Chronic levodopa is not toxic for remaining dopaminergic neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 43:561–575PubMedCrossRefGoogle Scholar
  30. 30.
    Mytilineou C, Han SK, Cohen G (1993) Toxic and protective effects of L-dopa on mesencephalic cell cultures. J Neurochem 61:1470–1478PubMedCrossRefGoogle Scholar
  31. 31.
    Obeso JA, Rodriguez-Oroz MC, Rodriguez M, DeLong MR, Olanow CW (2000) Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. Ann Neurol 47(Suppl):S22–S34PubMedGoogle Scholar
  32. 32.
    Oertel WH, Wolters E, Sampaio C, Gimenez-Roldan S, Bergamasco B, Dujardin M, Grosset DG, Arnold G, Leenders KL, Hundemer HP, Lledo A, Wood A, Frewer P, Schwarz J (2006) Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. Mov Disord 21:343–353PubMedCrossRefGoogle Scholar
  33. 33.
    Ogawa N, Tanaka K-I, Asanuma M, Kawai M, Masumizu T, Kohno M, Mori A (1994) Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res 657:207–213PubMedCrossRefGoogle Scholar
  34. 34.
    Okun MS, Watts RL (2002) Depression associated with Parkinson's disease. Neurology 58(Suppl 1):S63–S70PubMedGoogle Scholar
  35. 35.
    Olanow CW, Schapira AHV, Rascol O (2000) Continuous dopamine receptor stimulation in early Parkinson's disease. Trends Neurosci 23(Suppl):S117–S126PubMedCrossRefGoogle Scholar
  36. 36.
    Olanow CW (2002) The role of dopamine agonists in the treatment of early Parkinson's disease. Neurology 58:S33–S41PubMedCrossRefGoogle Scholar
  37. 37.
    Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Damier P, De Yebenes J, Gershanik O,Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, Langston WJ, LeWitt P, Melamed E, Mena MA, Michel PP, Mytilineou C, Obeso JA, Poewe W, Quinn N, Raisman-Vozari R, Rajput AH, Rascol O, Sampaio C, Stocchi F (2004) Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 19:997–1005PubMedCrossRefGoogle Scholar
  38. 38.
    Parkinson Study Group (1997) Safety and efficacy of pramipexole in early Parkinson's disease: a randomized dose-ranging study. JAMA 278:125–130CrossRefGoogle Scholar
  39. 39.
    Parkinson Study Group (2000) Pramipexole versus levodopa as initial treatment for Parkinson's disease. JAMA 284:1931–1938CrossRefGoogle Scholar
  40. 40.
    Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression. JAMA 287:1653–1661CrossRefGoogle Scholar
  41. 41.
    Parkinson Study Group (2004) Levodopa and the progression of Parkinson's disease. N Engl J Med 351:2498–2508CrossRefGoogle Scholar
  42. 42.
    Paus S, Brecht HM, Koster J, Seeger G, Klockgether T, Wullner U (2003) Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 18:659–667PubMedCrossRefGoogle Scholar
  43. 43.
    Pearce PKB, Banerji T, Jenner P, Marsden CD (1998) De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord 13:234–241PubMedCrossRefGoogle Scholar
  44. 44.
    Pearce RKB, Jackson M, Smith L, Jenner P, Marsden CD (1995) Chronic L-dopa administration induces dyskinesias in the 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus). Mov Disord 10:731–740PubMedCrossRefGoogle Scholar
  45. 45.
    Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 342:1484–1491PubMedCrossRefGoogle Scholar
  46. 46.
    Rascol O, Payoux, P, Ferreira J, Brefel-Courbon C (2002) The management of patients with early Parkinson's disease. Parkinsonism Relat Disord 9:61–67PubMedCrossRefGoogle Scholar
  47. 47.
    Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, Montastruc JL (2003) Limitations of current Parkinson's disease therapy. Ann Neurol 53(Suppl 3):S3–S15PubMedCrossRefGoogle Scholar
  48. 48.
    Razmy A, Lang AE, Shapiro CM (2004) Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol 61:97–102PubMedCrossRefGoogle Scholar
  49. 49.
    Rinne UK (1987) Brief communications. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a five year follow-up. Neurology 37:826–828PubMedGoogle Scholar
  50. 50.
    Rinne UK (1989) Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology 39:336–339PubMedGoogle Scholar
  51. 51.
    Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD (1998) Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double blind levodopa controlled trial. Drugs 55(Suppl 1):S23–S30CrossRefGoogle Scholar
  52. 52.
    Schapira AHV (2002) Neuroprotection and dopamine agonists. Neurology 58(Suppl 1):S9–S18PubMedGoogle Scholar
  53. 53.
    Schapira AHV, Olanow CW, Isacson, Rascol, Brooks, Tatton, Marek, Beal, Jenner (2003) Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. Ann Neurol 53(Suppl 3):S149–S159PubMedCrossRefGoogle Scholar
  54. 54.
    Schrag A, Quinn N (2000) Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 123:2297–2305PubMedCrossRefGoogle Scholar
  55. 55.
    Shannon KM, Bennet JP, Friedman JH (1997) Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology 49:724–728PubMedGoogle Scholar
  56. 56.
    Spencer JP, Jenner P, Daniel SE, Lees AJ, Marsden DC, Halliwell B (1998) Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J Neurochem 71:2112–2122PubMedCrossRefGoogle Scholar
  57. 57.
    Spencer JP, Jenner P, Halliwell B (1995) Superoxide-dependent depletion of reduced glutathione by L-DOPA and dopamine. Relevance to Parkinson's disease. Neuroreport 66:1480–1484CrossRefGoogle Scholar
  58. 58.
    Spina MB, Cohen G (1988) Exposure of striatal synaptosomes to l-dopa elevates levels of oxidized glutathione. J Pharmacol Exp Ther 247:502–507PubMedGoogle Scholar
  59. 59.
    Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, De Sutter J, Santens P, Decoodt P, Moerman C, Schoors D (2004) Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 363:1179–1183PubMedCrossRefGoogle Scholar
  60. 60.
    Walkinshaw G, Waters CM (1995) Induction of apoptosis in catecholaminergic PC12 cells by L-dopa. Implications for the treatment of Parkinson's disease. J Clin Invest 95:2458–2464PubMedCrossRefGoogle Scholar
  61. 61.
    Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ (2003) Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET Study. Ann Neurol 54:93–101PubMedCrossRefGoogle Scholar
  62. 62.
    Yoshikawa T, Minamiyama Y, Naito Y, Kondo M (1994) Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 62:1034–1038PubMedCrossRefGoogle Scholar

Copyright information

© Steinkopff-Verlag 2007

Authors and Affiliations

  1. 1.Dept. of Neurology, Rabin Medical Center-Beilinson CampusTel Aviv University, Sackler School of MedicineTel AvivIsrael

Personalised recommendations